Every 424B that VSEE HEALTH INC (VSEE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VSEE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSEE filings page.
VSee Health, Inc. filed a prospectus supplement and attached Form 8-K to update a resale registration that covers up to 33,808,195 shares of Common Stock. The registered shares comprise 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares, 9,836,065 Armistice pre-funded warrant shares and 19,672,130 Armistice warrant shares. The supplement incorporates a Form 8-K reporting receipt of a notice claiming an Event of Default under an 8% original issue discount secured promissory note in the aggregate principal amount of $271,739.13; the company is evaluating resolution alternatives.
VSee Health, Inc. filed a prospectus supplement registering for resale up to 33,808,195 shares of Common Stock by named selling stockholders, including 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares, 9,836,065 pre-funded warrant shares and 19,672,130 warrant shares. The supplement incorporates Form 8-K disclosure of a Standby Equity Purchase Agreement dated June 2, 2026 under which YA II PN, LTD. commits up to $10,000,000 in purchase capacity through June 2, 2029, subject to a Nasdaq Exchange Cap of 9,715,140 shares (approximately 19.99%) and an ownership limit of 4.99%. Pricing under the SEPA is set at 97% of the lowest daily VWAP during a three-consecutive trading day Pricing Period. The prospectus supplement and Prospectus govern resale mechanics; proceeds treatment is for selling stockholders.
VSee Health, Inc. filed a prospectus supplement registering the resale of up to 33,808,195 shares of Common Stock.
The supplement breaks that aggregate into 3,000,000 Manatt Shares; up to 1,300,000 Series B Shares; 9,836,065 pre-funded warrant shares; and 19,672,130 warrant shares. The supplement attaches a Form 8-K describing the sale of VSee Lab to Milton Chen, who agreed to transfer 2,870,069 shares of Common Stock back to the company and resigned as co-CEO and chair; Dr. Imoigele Aisiku is now sole CEO and chair. The common stock last reported at $0.1570 per share on Nasdaq on June 9, 2026.
VSee Health, Inc. registers for resale up to 33,808,195 shares of common stock for named selling stockholders, including shares issuable upon conversion of Series B preferred stock, warrants and pre-funded warrants. This prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The supplement covers resale by Manatt and Armistice from private placements and attaches updated financials showing cash of $1,346,132, an accumulated deficit of $85,016,985, and a reported net loss of $2,600,262 for Q1 2026. Management discloses substantial doubt about going concern for at least one year and lists measures being undertaken to address liquidity.
VSee Health, Inc. registers 33,808,195 shares of Common Stock for resale by the named selling stockholders.
The registration consists of 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares issuable upon conversion, 9,836,065 pre-funded warrant shares and 19,672,130 warrant shares. Shares outstanding were 47,299,421 as of March 30, 2026. The supplement incorporates the Form 10-K for the fiscal year ended December 31, 2025 and updates the prospectus; resale activity is by the selling stockholders.
VSee Health, Inc. registers 33,808,195 shares of Common Stock for resale under a prospectus supplement, including shares issuable upon conversion or exercise of preferred stock, warrants and pre-funded warrants.
The supplement ties to private placements that closed on December 1, 2025 and December 9, 2025, and updates the prospectus with proxy and Form 8-K disclosures. The company sought and obtained stockholder approval under Nasdaq Listing Rule 5635(d) for issuance of warrants exercisable for up to 19,672,130 shares. Shares outstanding were reported as 43,244,355 as of February 2, 2026.